What Is End-of-Life Care for Multicentric Castleman Disease?
By CRYSTAL BAI •
The short answer: Multicentric Castleman disease (MCD) — particularly the rare iMCD subtype — causes cytokine storm-like episodes and multi-organ dysfunction. End-of-life care addresses systemic inflammation, organ failure, and the unique burden of a disease that can be sudden and unpredictable.
Understanding Multicentric Castleman Disease at End of Life
Castleman disease encompasses a group of rare lymph node disorders. Unicentric CD (single site) is curable with surgery. Multicentric CD (MCD) — particularly idiopathic MCD (iMCD) and the HHV-8 associated form — involves systemic inflammatory flares affecting multiple organs. When iMCD is refractory to siltuximab and other therapies, end-of-life care may become appropriate.
The Unpredictable Course of Severe MCD
Severe iMCD can cause sudden, life-threatening cytokine storm-like episodes (TAFRO syndrome — thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly) that carry high mortality. The unpredictable, episodic nature of severe MCD makes advance care planning particularly important — patients may need ICU care suddenly during a flare.
Systemic Symptom Management
Advanced MCD causes severe constitutional symptoms, anasarca (generalized edema), multi-organ dysfunction, cytopenias, and systemic inflammation. Palliative management focuses on fluid management, symptom control, infection prevention, and organ-specific support.
Patient Community and Resources
The Castleman Disease Collaborative Network (CDCN) is the primary resource for Castleman disease patients and families, providing information, research updates, and patient community. Connecting with CDCN while pursuing treatment and end-of-life planning helps patients and families navigate this rare disease.
Frequently Asked Questions
What is multicentric Castleman disease?
MCD is a rare lymph node disorder causing systemic inflammatory flares involving multiple organs. Severe iMCD can cause life-threatening cytokine storm episodes.
When should an MCD patient consider hospice?
Hospice is appropriate when MCD is refractory to available therapies, causing severe organ dysfunction, and prognosis is six months or less.
What symptoms are managed at end of life with MCD?
Key symptoms include severe constitutional symptoms, anasarca, multi-organ dysfunction, cytopenias, and the unpredictable flare pattern of severe disease.
Can a death doula help a family facing MCD end of life?
Yes. Death doulas provide family support, advance planning assistance, and help connect families to the Castleman Disease Collaborative Network and rare disease resources.
Renidy connects grieving families with compassionate death doulas and AI-powered funeral planning tools. Try our free AI funeral planner or find a death doula near you.